Download Report

ARCC CONFERENCE 2015
O
Canada’s Applied Research in Cancer Control Conference
PRELIMINARY PROGRAM
May 24 – 25, 2015 • Montréal, Québec
Hotel Bonaventure Montréal
www.cc-arcc.ca
PROGRAM AGENDA
ARCC Conference 2015 • May 24-25, 2015
Sunday, May 24, 2015
1:30pm – 3:30pm
FIRESIDE CHAT WORKSHOP
Cancer Drug Funding and Access: A Fireside Chat
Presented by GILLES PINEAU, MD, INESS; MONA SABHARWAL, PharmD, pCODR; and CHARLOTTE CHAMBERLAIN, MRCP
4:00pm – 5:00pm
SPEED NETWORKING
5:00pm – 7:00pm
ARCC WELCOME RECEPTION / POSTER VIEWING SESSION A
Join your event hosts and fellow participants for a beverage, some light snacks and an opportunity to network in advance of the
conference as well as view the first series of poster presentations being presented at the conference.
Monday, May 25, 2015
7:30am – 8:30am
REGISTRATION / BREAKFAST
8:30am – 8:35am
WELCOME FROM THE CO-DIRECTORS
8:35am – 8:40am
WELCOME FROM THE CANADIAN CANCER SOCIETY
8:40am – 10:15am
PLENARY PRESENTATION
PSA Testing in Prostate Cancer
Chaired by ALICE DRAGOMIR
Presented by ANDREW LOBLAW, ROCCO ROSSI and FERNAND TURCOTTE
10:15am – 10:35am
NUTRITION BREAK
10:35am – 12:05pm
CONCURRENT SESSIONS A
A1
A1.1
DRUG EVALUATION & POLICY MAKING
Use Of Linked Health Administrative Data To Support Policy Change For Child Cancer Survivor Care
Presented by MARY MCBRIDE
A1.2
Engaging The Public On Funding For Cancer Drugs: Results From A Public Deliberation Event On Priority Setting And Cancer
Drug Funding In Vancouver, BC
Presented by COLENE BENTLEY
A1.3
Cancer Formulary Recommendations In Canada - A Revealed Preferences Analysis
Presented by DOMINIKA WRANIK
A1.4
An Assessment Of The Pan-Canadian Oncology Drug Review Economic Evaluations: Insights For Submitters And Reviewers
Presented by LISA MASUCCI
A1.5
Managing Uncertainty In Policy Decision Making About Cancer Control: A Qualitative Study Of Canadian Policymakers
Presented by MICHELLE DRIEDGER
2
A2
A2.1
METHODOLOGY
Estimating Uncertainty Impact In Fixed-Value Decision Model Parameters – An Example In Genome-Guided Oral Premalignant Lesions
Presented by IAN CROMWELL
A2.2
Micro-Costing Of High-Throughput Genomic Assays Using A Time-Motion Approach
Presented by SARAH COSTA
A2.3
Utilizing Iterative Benefits Evaluation to Develop and Improve an Electronic Navigational Tool for Cancer Diagnostic Testing:
A Model for Strategically Shaping the e-Health Landscape
Presented by MELISSA KAAN
A2.4
Integrating Care For Cancer Patients – Health Care Utilization Across Levels Of Complexity
Presented by MARNIE MACKINNON
A2.5
The Protective Effects Of Social Relationships On Mortality: Is There Something Different About Cancer?
Presented by JAMES IVENIUK
A3
A3.1
PROSTATE CANCER
Castration-Resistant Prostate Cancer (CRPC): Evaluation Of The Quality Of Care And Disease Management In Real-Life Setting
Presented by HALIMA LAHCENE
A3.2
Cost-Effectiveness Of Multiparametric Mri And Targeted Biopsy In Diagnosing Prostate Cancer
Presented by ALICE DRAGOMIR
A3.3
Cost-Effectiveness of Prostate Cancer Management Strategies in Canada
Presented by CHIRANJEEV SANYAL
A3.4
Use Of Docetaxel And Abiraterone In The Management Of Castration-Resistant Prostate Cancer In Quebec: A Real-World
Cost-Effectiveness Study
Presented by JOICE ROCHA
A3.5
Understanding Readmission Rates following Radical Prostatectomy
Presented by JACQUELINE GREGORY
12:05pm – 12:45pm
NETWORKING LUNCH
12:45pm – 1:30pm
POSTER VIEWING SESSION B
View the second series of poster presentations being presented at the conference.
1:30pm – 3:00pm
CONCURRENT SESSIONS B
B1
B1.1
COSTING OF THE CANCER SYSTEM
Health System Costs Of The Pre-Diagnosis Phase In Neuroendocrine Tumours
Presented by SIMRON SINGH
B1.2
Comparing Phase-Based Costs Of Cancer Care In British Columbia And Ontario
Presented by REKA PATAKY
B1.3
Estimating The Net Costs Of Cancer Care Before And After Diagnosis For Childhood Cancer In Ontario
Presented by CLAIRE DE OLIVEIRA
B1.4
Costs of Cervical Cancer Treatment: Estimates from Ontario, Canada
Presented by CIARA PENDRITH
B1.5
A Time-Trend Economic Analysis Of Cancer Drug Trials
Presented by SONYA CRESSMAN
3
B2
B2.1
REAL LIFE DATA ON SCREENING, DIAGNOSIS, AND SURVIVAL
Breast Cancer Subtypes And Screening Mammography Sensitivity
Presented by LINDA PERRON
B2.2
Using Administrative Data To Estimate Time To Breast Cancer Diagnosis And Percent Of Screen-Detected Breast Cancers – A
Validation Study
Presented by YAN YUAN
B2.3
Treatment Of Taxane Acute Pain Syndrome (Taps) In Patients Receiving Taxane Chemotherapy For Breast And Prostate
Cancers – A Systematic Review And Network Analysis
Presented by RICARDO FERNANDES
B2.4
Predictors Of Actual Survival In Resected Pancreatic Adenocarcinoma: A Population-Level Analysis
Presented by DANIEL KAGEDAN
B2.5
Phase-Specific Health Care Costs Of Cervical Cancer: Estimates From A Population-Based Study
Presented by NING LIU
B3
B3.1
QUALITY IMPROVEMENT
Evaluating the Impact of PET Scanning for Lymphoma Patients: Development of the Ontario PET Lymphoma Staging Registries
Presented by PAMELA MACCROSTIE
B3. 2
Target Setting for Palliative Care Wait Times at Ontario Regional Cancer Centres
Presented by VICTORIA ZWICKER
B3. 3
Do We Need To Improve The Coordination Of Multidisciplinary Care For Patients With Head And Neck Cancer? An Investigation
Of Unplanned Hospital Emergency Department Visits By Patients With Oropharyngeal Cancer In Ontario?
Presented by ELIZABETH LOCKHART
B3. 4
Optimizing the Design of a Population-Based Reflex Testing Program for Lynch Syndrome in Ontario: Health Care Providers’
Perspectives
Presented by YVONNE BOMBARD
B3. 5
Thinking Differently About The Kids: An Innovative Approach to Improve Care Provided to pediatric Patients Undergoing
External Beam Radiation Therapy
Presented by KATHERINE JENSEN
3:00pm – 3:20pm
NUTRITION BREAK
3:20pm – 4:55pm
PLENARY PRESENTATION – Sustainability of the Cancer System
Sustainability of the Cancer System
Chaired by JEAN ROUSSEAU
Presented by CRAIG EARLE, CHANTAL KROON and RAGHU RAJAN
4:55pm – 5:05pm
4
POSTER AWARDS & CLOSING REMARKS
CONFERENCE CO-CHAIRS & JUDGING COMMITTEE
ALICE DRAGOMIR – CONFERENCE CO-CHAIR
Dr. Alice Dragomir is a Medical Scientist with the McGill University Health Centre and an Assistant Professor in the Division of Urology –
Department of Surgery at McGill University. Alice’s research focuses on improving the manner in which health care is delivered to patients
with prostate cancer, and for ways to optimize cost allocation for services. Alice joined ARCC in 2013, and has recently committed to Associate
member status.
JEAN ROUSSEAU – CONFERENCE CO-CHAIR
Dr. Jean Rousseau has been a scientific manager at the Institut national de santé publique du Québec (INSPQ) since 2008. At the INSPQ, Dr.
Rousseau heads the unit Analyse des politiques de dépistage et lutte contre les maladies chroniques, which is mandated by the Québec
Ministry of Health and Social Services to evaluate the implementation of prenatal, newborn and cancer screening programs in Québec.
Jean’s current research topics include economic evaluation modalities of screening programs and costing analysis of screening practices.
Jean joined ARCC in 2012, and is an ARCC Investigator.
SYLVIE LAMBERT – CHAIR, JUDGING COMMITTEE
Dr. Lambert joined McGill University from Australia where she was a National Health and Medical Research Council (NHMRC) Research
Fellow at the Translational Cancer Research Unit, Ingham Institute for Applied Medical Research, University of New South Wales. Her
national and international standing in the area of patient education, information-seeking, caregiver research, sustainable self-management
interventions, longitudinal research, and psychometrics are evidenced by high-quality publications, including winning several prizes for
these and attracting highly competitive funding. Her most significant studies have included Australia’s first longitudinal caregiver well-being
study, and developing a self-directed coping skills training and self-management interventions for couples facing cancer called CopingTogether. Dr. Lambert now plans to expand the reach of Coping-Together to patients and caregivers with low literacy and from culturally and
linguistically diverse backgrounds.
SPEAKER BIOS
DR. CHARLOTTE CHAMBERLAIN is a public health and palliative care doctor currently working at the University of Bristol and the Bristol
Royal Infirmary. Dr Chamberlain trained in Medicine at the Royal Free and University College London Medical School and intercalated a
degree in Global Health. Following a Masters in Epidemiology, at the London School of Hygiene and Tropical Medicine, Dr Chamberlain has
pursued a career in public health medicine in the South West region of England (2008 to present day). She is currently completing a PhD
on ‘access to non-curative anti-cancer therapies on the NHS’ funded by the National Institute for Health Research (UK) at the University of
Bristol. Her research interests, around cancer at the end of life and balancing priorities in publicly-funded health systems, have informed the
on-going debate about the rationale for the Cancer Drugs Fund in England.
DR. CRAIG EARLE, MD, MSC is a medical oncologist specializing in gastrointestinal cancers at Sunnybrook’s Odette Cancer Centre, the
Director of Health Services Research for Cancer Care Ontario and the Ontario Institute for Cancer Research, a Professor of Medicine at
the University of Toronto, and a Senior Scientist at the Institute for Clinical Evaluative Sciences. Dr. Earle originally trained and practiced in
Ottawa, after which he spent 10 years between 1998 – 2008 in Boston at Harvard Medical School and the Harvard School of Public Health.
While there, he was the founding Director of the Lance Armstrong Foundation Adult Survivorship Clinic at Dana-Farber Cancer Institute. He
is currently Chair of the Ontario Steering Committee for Cancer Drug Programs. His personal research interests focus on evaluating and
improving the quality of care received by patients with advanced cancer and cancer survivors, the effect of financial incentives on care
delivery, and making linked de-identified administrative data more available for health research.
CHANTAL KROON, BSCN, MA completed her bachelor’s degree in Nursing at Laval University in 1990, and a Master’s degree in Medical
Law and Ethics at King’s College, University of London, UK, in 1993. She served primarily as a clinician working with pediatric, adult, and
elderly patients at University Hospitals (Quebec and Switzerland), in community health settings, and in long-term care facilities. She also
taught nursing at college and university levels. For the past fifteen years, she has held management positions in the Quebec health network
and at the Quebec Ministry of Health and Social Services (MSSS). She has been in charge of provincial mandates on issues related to
chronic diseases, primary care services and service trajectory for elderly within the health network, including those who accessed it through
emergency departments. She is currently responsible for provincial workforce planning in nursing, as well as initial and continuous training.
5
DR. ANDREW LOBLAW, MD, FRCPC, MSC is a Radiation Oncologist, Clinician Scientist, and dual Professor in the Department of Radiation
Oncology and the Institute of Health Policy Management & Evaluation at the University of Toronto. He received a Bachelor of Science in
Physics from the University of British Columbia and his Doctor of Medicine from Queen’s University. He completed his specialty training
in Radiation Oncology concurrent with a Masters degree in Clinical Epidemiology to graduate from Royal College’s Clinician Investigator
Program all at the University of Toronto. Dr. Loblaw’s clinical practice and research interest focus on improving outcomes for men with
prostate cancer and the healthcare system. He has a particularly interest in the design and conduct of clinical trials, the generation and
dissemination of evidence-based guidelines and in image-guided radiotherapy. Dr. Loblaw is an Ontario Association of Radiation Oncology
Clinician Scientist and a Scientist at the Sunnybrook Research Institute. He is Medical Director for Sunnybrook International’s Prostate
Cancer Centres of Excellence, the North American Editor for Clinical Oncology, the Co-Chair of the American Society of Clinical Oncology’s
Genitourinary Advisory Group, and Co-Chair of the GU group for Cancer Care Ontario’s Program in Evidence-Based Care. He has authored
over 150 peer-reviewed papers and has been awarded grant funding of over $17M.
DR. GILLES PINEAU, MD is coordinator of the INESSS Oncology Assessment Unit. He holds a bachelor’s degree in engineering physics from
Université Laval and a doctorate in medicine from the Université de Montréal. Cofounder of the ACTI-MENU Health Program, he served as
its president and director from 1987 to 2003. For about a decade, he worked within the occupational health department of Hydro-Québec in
various capacities, most notably as medical director. He has extensive experience in oncology. He was a scientific advisor for the Canadian
Cancer Society, Québec Division, where he also served as president and for 10 years as a member of the board of directors. Furthermore,
he served on the national board of directors of this Society. His work in the Université de Montréal Faculty of Medicine included serving as
director of the family medicine program and multidisciplinary internship program. Concurrently, he headed the department of minor and
major emergencies at the Hôtel-Dieu de Montréal, and was the founding president of the Clinique médicale de la Cité. A few years ago,
together with a collaborating partner, he founded Le Point en Administration de la Santé et des Services Sociaux, a publication aimed at a
readership made up of health care system administrators. Dr. Pineau currently chairs the publication’s board of directors.
DR. RAGHU RAJAN, MD, MSC is a medical oncologist at the McGill University Health Centre with an interest in the management of colorectal
cancer and genitourinary cancers, and serves as the disease site lead for lower gastrointestinal cancers at the MUHC. He is Associate
Professor of Oncology and Medicine at McGill University, and chairs the Pharmacy and Therapeutics Committee of the MUHC. Dr. Rajan is a
member of the Comité de l’evolution des pratiques en oncologie (CEPO) within INESSS and is also a member of the Programme de gestion
thérapeutique des medicaments (PGTM), an initiative involving the five teaching hospitals in Quebec. After receiving his medical degree at
the University of Manitoba and going through internship at McGill University, Dr. Rajan completed his training in internal medicine at the Mayo
Graduate School of Medicine. He subsequently undertook subspecialty fellowships in haematology and medical oncology, as well as a Terry
Fox research fellowship concurrent with a Master’s degree in clinical epidemiology at McMaster University.
ROCCO ROSSI, BA, MA – A successful entrepreneur and business executive, champion fundraiser, and dedicated public servant, Rocco
Rossi is currently President and CEO of Prostate Cancer Canada. As CEO of the Heart and Stroke Foundation – one of Canada’s largest nonprofit organizations – from 2004 to 2009, Rossi oversaw four consecutive years of record fundraising raising over $500 million in total and
launching many new, life-saving initiatives. His passion for public policy has led him to stand for election both for the position of Mayor of
Toronto and for MPP. Mr. Rossi has held senior positions at the Boston Consulting Group, TORSTAR, Labatt/Interbrew and MGI Software. A
past board member of United Way of Greater Toronto and other charities, Mr. Rossi has been an active community builder. In fact, in 2012
he was awarded the Queen’s Jubilee Medal for his Philanthropic and Community service. A dedicated adventurer, Rocco has walked the
legendary Camino de Santiago 7 times, cycled the 1900 km length of Yonge Street from Rainy River to Toronto, kayaked the 500 km from
Toronto to Ottawa, and climbed to Everest Base Camp. Mr. Rossi has a BA (Hons) in political science from McGill University and a Masters of
Arts in politics from Princeton University. He is married to his wife of 27-years, Rhonnie, and they have a 25-year-old son, Domenic John, who
attends OISE in Toronto where he is working on his Masters in Teaching.
DR. MONA SABHARWAL is the inaugural Executive Director of the pan-Canadian Oncology Drug Review (pCODR). In this leadership role, she
had responsibility to implement and operationalize a new national initiative, engaging a broad spectrum of decision makers and stakeholder,
establishing a new standard for how pharmaceutical HTA is conducted in Canada and leading to pCODR’s successful launch in July 2011. In
April 2014, she successfully implemented the operational integration of pCODR into CADTH and is now leading Phase 2 of the transfer which
will be looking at policy alignment of pCODR and the Common Drug Review programs. She has worked in drug technology assessment and
formulary management, in both British Columbia and Ontario, for approximately 20 years. Before joining pCODR, she was the Senior Manager
for Drug Programs Management with the Ontario Ministry of Health and Long-Term Care. In this role, she had operational oversight of the
drug submission and evaluation process for Ontario’s public drug programs. Dr. Sabharwal is a registered pharmacist with experience in both
community and hospital pharmacy practice. She has also conducted practice-based research focused on finding concrete ways to improve
the delivery of pharmacist-based professional services. She obtained both her Bachelor of Science in Pharmacy and her Doctor of Pharmacy
from the University of Toronto.
DR. FERNAND TURCOTTE, MD, MPH, FRCPC is professor emeritus of preventive medicine and public health at Université Laval. As a cofounder of the department of social and preventive medicine, most of his research activities have borne on the prevention of chronic
diseases associated with toxic exposures either in the workplace or in the general environment. The evaluation of prevention strategies is a
field to which he has made contributions. He has been involved for three decades in the shaping of public policies required to improve the
protection of the health of the nation, in tobacco control and exposure to asbestos. Dr. Turcotte have completed my studies in medicine at
the U of Montreal school of medicine (1967) and his Master in Public Health at Harvard University (1971). Dr. Turcotte has taught at Université
Laval for all my career (1971-2005).
6
POSTER PRESENTATIONS AT-A-GLANCE
HEALTH SYSTEMS, SERVICE & POLICY
1
Improving Patient Safety Through Standardized Pre-Printed Orders For Take-Home Chemotherapy
Presented by NITA LAKHANI Pharmacist, Drug Formulary, CPQI, Cancer Care Ontario
2
Health Services Utilization In The End-Of-Life Phase Of Patients Dying Of Prostate Cancer In Quebec Between 2001 and 2013
Presented by JASON HU MSc Student, McGill University
3
Improving The Quality And Safety Of Radiation Treatment: Implementing Radiation Oncology Peer Review At A Jurisdictional Level In Ontario
Presented by LINDSAY REDDEMAN Cancer Care Ontario
4
Population Based Analysis Of Breast Cancer Diagnosis In Alberta
Presented by YAN YUAN University of Alberta
5
Locally Advanced Colorectal Cancer – A Population-Based Study Of Factors Associated With Relative Excess Risk Of Death
Presented by LINDA PERRON Médecin spécialiste, Institut national de santé publique du Québec
6
Treatment Of Castration-Resistant Prostate Cancer In A Real-Life Setting In Quebec
Presented by JOICE ROCHA Ph.D., Urology,Department of Surgery, McGill University Health Center
7
Using Canadian Administrative Data To Understand The Interplay Between Primary And Oncology Care For Breast Cancer Patients During PreDiagnosis, Treatment And Survivorship: A CanIMPACT Study
Presented by PATTI GROOME Professor, Queen’s University
8
Developing A Capacity Planning Model For Positron Emission Tomography Scans In Ontario
Presented by JONATHAN WANG Cancer Care Ontario
9
Examining The Use Of An Advanced Practice (AP) Radiation Therapy (RT) Role, The Clinical Specialist Radiation Therapist (CSRT) A New Model
Of Care
Presented by MICHELLE ANG Policy Research Analyst, Cancer Care Ontario
10
Cervical Cancer Screening In Ontario’s Primary Healthcare Practice Models: The Influence Of Financial Incentives
Presented by CIARA PENDRITH Western University
11
Providing Better Care Together: The Acute Leukemia Shared-Care Program
Presented by AMANDA WONG Cancer Care Ontario
12
Leveraging Competition For Quality Improvement In The Canadian Context
Presented by VICTORIA HAGENS Manager, Regional Programs and Performance Management, Cancer Care Ontario
13
Pilot Implementation Of Survivorship Care Plans – An Update
Presented by FRANCES WONG BC Cancer Agency
HEALTH TECHNOLOGY ASSESSMENT
14
Conducting Economic Evaluations To Inform Policy In Ontario: Example Of Docetaxel For Treatment Of Castrate-Sensitive Prostate Cancer
Presented by JACLYN BECA Manager, Pharmacoeconomics Research Unit, Cancer Care Ontario
15
pCODR Experience With Progression Free Survival In Assessing Treatment Clinical Benefit
Presented by ALEXANDRA CHAMBERS
16
Estimate The Clinical And Economic Impact Of Urologists’ Adherence To The Follow-Up Guidelines After Radical Or Partial Nephrectomy For
Localized And Locally Advanced Renal Cell Carcinoma In Canada
Presented by ALICE DRAGOMIR McGill University
17
A Cost-Effectiveness Analysis Of Intra-Lesional Il-2 For The Treatment Of Unresectable In-Transit Melanoma
Presented by JACLYN BECA Manager, Pharmacoeconomics Research Unit, Cancer Care Ontario
18
A Literature Review Of Economic Evaluations Of Smoking Cessation Programs In The Oncology Setting
Presented by WANRUDEE ISARANUWATCHAI Health Economist, Cancer Care Ontario
7
19
A Data-Driven Model To Support Health Human Resource (HHR) Prediction And Planning
Presented by JUNELL D’SOUZA Planning Officer, Cancer Care Ontario
20
Estimating Long-Term Cancer Costs Of Cancer Care In Ontario
Presented by CLAIRE DE OLIVEIRA Independent Scientist/Health Economist, CAMH
21
Resource Utilization And Costs Of Managing Patients With Advanced Metastatic Melanoma: A Population Based Study
Presented by NICOLE MITTMAN HOPE Research Centre
22
The Impact Of Aggressive Management And Palliative Care On Cancer Costs In The Final Month Of Life
Presented by NICOLE MITTMAN HOPE Research Centre
23
Generating Costing Algorithms For Oncology Drugs Using Administrative Databases
Presented by NICOLE MITTMAN HOPE Research Centre
24
Patient Navigation In Cancer Care: Is There Any Evidence Of Cost-Effectiveness?
Presented by LISA PARVIN University of British Columbia
KNOWLEDGE TRANSLATION
25
Communities Of Practice: A Model For Improving Quality Of Care In Radiation Treatment
Presented by ELIZABETH LOCKHART Cancer Care Ontario
26
A Mobile App For Primary Care Providers: Cancer Care Ontario’s Cancer Screening App
Presented by ZEINAB EL-MASRI Sr. Analyst, Cancer Care OntarioCo-Author(s): Priyanka Raj, Cancer Care Ontario / Lorna Dobi, Cancer Care Ontario / Laura
Heller, Cancer Care Ontario / Dafna Carr, Cancer Care Ontario
27
A Systematic Review Of The Incidence Of Taxane Acute Pain Syndrome (TAPS) In Patient Receiving Taxane-Based Chemotherapy For Breast And
Prostate Cancers
Presented by RICARDO FERNANDES The Ottawa Hospital Cancer Centre
28
A National Rectal Cancer Quality Initiative: A Novel Approach To System Improvement
Presented by GUNITA MITERA Quality Initiatives Specialist, Canadian Partnership Against Cancer
29
Rethinking Clinical Trials (REACT) In Ontario: Evaluating The Feasibility Of Using An Integrated Consent Model To Compare Standard Of Care
Treatments
Presented by MARK CLEMONS Ottawa Hospital Research Institute
30
Advancing Evidence-Based Dietary Assessment In Canada To Enhance Cancer Prevention And Survivorship Research
Presented by SHARON KIRKPATRICK University of Waterloo
31
Synoptic Radiology Reporting: Tool for Knowledge Translation and Exchange from Development to Implementation
Presented by PRIYANKA JAIN Project Coordinator, Cancer Care Ontario
32
Leveraging TRA Data To Assess Potential Asbestos Exposure In Ontario
Presented by SHEILA KALENGE Occupational Cancer Research Centre
PATIENTS & FAMILIES
33
Differences In Patient Quality Of Life For Leukemia Treatment Strategies
Presented by EMILY MCPHERSON Health Economist, ARCC
34
Preferences Of Cancer Patients On Method Of Collecting Patient Reported Outcomes Using The Edmonton Symptom Assessment System
(Esas)-Distress Assessment Response Tool (DART)
Presented by WYANNE LAW Medical Student, Princess Margaret Cancer Centre
35
Advanced Basal Cell Carcinoma (ABCC) Patients’ Health Value From Physicians’ Perspective
Presented by POOYEH GRAILI SMH
36
A Systematic Review Of Interventions To Improve Sexual Dysfunction In Cancer Patients And Survivors
Presented by JACQUELINE LIBERTY Research Associate, Cancer Care Ontario
8
37
What Does Satisfaction With Wait Times Mean To Cancer Patients?
Presented by DANA RYAN Memorial University of Newfoundland
38
Preferential Access To Cancer Care? Patient Experiences Of Efforts To Reduce Wait Times
Presented by DANA RYAN Memorial University of Newfoundland
39
Information And Its Impact On Co-Survivors Of Cancer Patients
Presented by VIOLET D’SOUZA University of Montreal
40
Is More Homecare Nursing Associated With Fewer Hospitalizations At The End Of Life?: A Multi-Provincial Cancer Cohort Study
Presented by ERIN O’LEARY Research Coordinator, McMaster University
41
Sustainable Action For Improved Outcomes In Adolescents And Young Adults (AYA) With Cancer In Canada – The Canadian Task Force (TF) On
AYA With Cancer: 2015 And Beyond
Presented by SONJA DE PAUW Canadian Task Force on AYA Cancer
SOCIETAL VALUES & PUBLIC ENGAGEMENT
42
Cancer Drug Shortages: System Lessons From Recent Cases
Presented by AMANDA CHAN Cancer Care Ontario
43
Inequalities In Access To Treatment On The Cancer Drugs Fund In England
Presented by CHARLOTTE CHAMBERLAIN University of Bristol, School of Social and Community Medicine
44
Awareness To Taking Action: How Did A Community Raise Awareness And Take Action On Behalf Of Workers Who Have Been Exposed To Asbestos
Presented by DESRE KRAMER Staff scientist and Associate Director, Occupational Cancer Research Centre, Cancer Care Ontario
45
Social Values In The Assessment Of Health Technologies For Childhood Cancer
Presented by AVRAM DENBURG McMaster University/Hospital for Sick Children, University of TorontoCo-Author(s): Avram Denburg, McMaster
University/Hospital for Sick Children
46
Attitude To Health Risk In The Canadian Population
Presented by NICK BANSBACK Assistant Professor, University of British Columbia
47
Identifying A “Representative Public”: Recruiting For Demographic And Values Diversity For A Public Engagement Event On Priority Setting And
Cancer Drug Funding In Vancouver, BC
Presented by DEAN REGIER Senior Health Economist, ARCC-BCCA
48
A Process To Identify Research Priorities In A Multi-Sector Group
Presented by MICHELLE REID Cancer Prevention Centre, UBC
49
Inequality By Race/Ethnicity In Survival Improvement Of Children With Acute Lymphoblastic Leukemia In The United States And Canada
Presented by LINWEI WANG Master Student, University of Alberta, School of Public Health
9